Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes

Objective: To determine the relationship between abnormalities in blood coagulation and prevalent or incident cardiovascular complications in Type 2 diabetes. Design and methods: Prospective cohort study of 128 patients with Type 2 diabetes in whom blood samples were collected at baseline and after...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2006-03, Vol.4 (3), p.574-580
Main Authors: SOMMEIJER, D. W., HANSEN, H. R., VAN OERLE, R., HAMULYAK, K., VAN ZANTEN, A. P., MEESTERS, E., SPRONK, H. M. H., TEN CATE, H.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers - blood
Blood Coagulation
Cardiovascular Diseases - blood
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - etiology
diabetes mellitus Type 2
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetic Angiopathies - blood
Diabetic Angiopathies - epidemiology
Diabetic Angiopathies - etiology
Disease Progression
Female
Humans
Male
microvascular disease
Middle Aged
soluble tissue factor
Thromboplastin - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To determine the relationship between abnormalities in blood coagulation and prevalent or incident cardiovascular complications in Type 2 diabetes. Design and methods: Prospective cohort study of 128 patients with Type 2 diabetes in whom blood samples were collected at baseline and after 1 year of follow‐up. All cardiovascular complications at baseline and follow‐up were recorded. Forty‐three healthy, age‐matched subjects served as a control group. Results: Logistic analysis revealed an independent relationship between soluble tissue factor (TF) and microvascular disease [per pg mL−1 TF: Exp(B) = 1.008; CI(95%)1.002–1.014], or neurogenic disease [Exp(B) = 1.006; CI(95%)1.001–1.011]. The highest levels of soluble TF were observed in patients with microvascular and neurogenic disease (P 300 pg mL−1 are at a 15‐fold higher risk for the presence of microvascular disease and at a 10‐fold higher risk for the presence of neurogenic disease compared with the patients with concentrations below 100 pg mL−1. Soluble TF was correlated with tissue type plasminogen activator, von Willebrand factor antigen, systolic blood pressure and age. Levels of F1′ + 2, D‐dimer, FVIII activity, t‐PA and vWFag were not different among patients with micro‐, macro‐ or neurogenic complications compared with patients without those complications. Forty‐eight new micro‐, macro‐ and/or neurogenic complications were diagnosed after 1 year follow‐up. With the exception of higher F1 + 2 levels after 1 year all other markers remained unchanged. A trend toward higher soluble TF levels was observed in patients with new microvascular events (P = 0.056). Conclusions: Soluble TF is associated with existing microvascular and neurogenic complications in patients with Type 2 diabetes and is a candidate marker for progression of microvascular disease.
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/j.1538-7836.2005.01763.x